Actively Recruiting
Assessment of Pancreatic Beta-Cell Reserve Using Alpelisib Challenge Test and Hyperglycemic Clamp in Adults with Varying Body Weights
Led by Columbia University · Updated on 2026-09-03
15
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate a simpler method for measuring how much insulin a person can produce compared to the current standard, the hyperglycemic clamp. The study focuses on pancreatic beta-cell reserve, which plays a key role in type 2 diabetes development, and aims to improve oral-based tests by using a drug called alpelisib to create temporary insulin resistance. This approach may provide a more accurate assessment of insulin secretion. Participants will stay overnight in a clinical research unit for about 30 hours. On the first morning, they will undergo a two-hour hyperglycemic clamp involving an intravenous glucose infusion to measure insulin production. Throughout the day, they will consume standardized meals, and at 1100 PM, they will take a single 300 mg dose of alpelisib. The next morning, they will complete a Mixed Meal Tolerance Test by drinking a standardized nutritional beverage while blood samples are taken periodically. During the study, researchers will monitor insulin secretion and other related measures using blood tests taken during both the clamp and the meal tolerance test after alpelisib dosing. They will measure outcomes such as insulin and C-peptide levels, insulin secretion rate, and clearance rate. The main goal is to see how well the new test correlates with the traditional clamp method, with the total participation lasting about 30 hours.
CONDITIONS
Brief Title
Alpelisib Challenge Test (ACT)
Research Team
J
Joshua R Cook, MD, PhD
I
Ishwari Nagnur
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here